Spring til hovednavigatio
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
COVID-19
100%
Nucleocapsid Antigen
34%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
30%
Neutralizing Monoclonal Antibody
25%
Placebo
22%
Randomized Controlled Trial
22%
Therapeutic Monoclonal Antibody
22%
Clinical Biomarkers
22%
Hospitalization
19%
Hospitalized Patients
18%
Comorbidity
16%
Interleukin-6
14%
Clinical Outcomes
14%
Viral Factors
13%
Tixagevimab
12%
Sotrovimab
12%
Vaccination
12%
Placebo Groups
12%
C-reactive Protein
12%
Antigen Levels
11%
Bivalent Vaccination
11%
World Population
11%
Predictors of Hospitalization
11%
Ensovibep
11%
Randomized Double-blind
11%
Nonrecovery
11%
Absolute Lymphocyte Count
11%
Lymphopenia
11%
Anti-nucleocapsid Antibody
11%
Immunological Response
11%
Vaccine Response
11%
Virological Markers
11%
SARS-CoV-2 Vaccine
11%
Omicron Variant
11%
Breakthrough Infection
11%
T Cell Immunity
11%
Prospective Cohort Study
11%
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
11%
BA.1
11%
Systemic Response
11%
Host Factors
11%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
11%
National Cohort Study
11%
BA.4
11%
Age Impact
11%
Virologic
11%
Viral
9%
Sustained Recovery
9%
Risk Factors
9%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
65%
COVID-19
63%
Virus Nucleocapsid
36%
Antigen
30%
Blood Plasma
27%
Spike
17%
Infection
17%
Infectious Disease
17%
Comorbidity
16%
Monoclonal Antibody
12%
Interleukin 6
12%
Immune Response
11%
Adoptive Immunity
11%
Host Factor
11%
Lymphocyte Count
11%
Lymphocytopenia
11%
Omicron Coronavirus Variant
11%
Immunoglobulin G
9%
C-Reactive Protein
8%
Breakthrough Infection
6%
Ribonucleic Acid
5%
Virus
5%
Antibody Response
5%
Medicine and Dentistry
COVID-19
44%
Severe Acute Respiratory Syndrome Coronavirus 2
20%
Antigen
18%
Placebo
15%
Biological Marker
11%
Prospective Cohort Study
11%
Host Factor
11%
Interleukin 6
9%
Diseases
6%
C Reactive Protein
6%
Hazard Ratio
6%
Virus
5%
Immune Response
5%
Virus RNA
5%